Amgen seeks license for biosimilar version of oncology drug Rituxan

You are here: Home > Biotech > Current Article

Amgen seeks license for biosimilar version of oncology drug Rituxan

By Staff Report / Thursday, December 19th, 2019 / Comments Off on Amgen seeks license for biosimilar version of oncology drug Rituxan

On the heels of its third U.S. approval for a biosimilar, Amgen submitted an application to regulators for an oncology drug imitating Rituxan, a $5 billion drug made by Roche. The Thousand Oaks biotech giant said it submitted a biologics license application to the U.S. Food and Drug Administration for its product ABP 798 in…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.